According to the Department of Justice (DOJ), Haywood spoke to a representative of Neurotrope on the day it put out news of a $2.7 million grant from the National Institutes of Health following the release of data from an Alzheimer’s disease clinical trial. The news caused Neurotrope’s share price to double, but, on the call with a representative of the biotech, Haywood learnt of a stock offering that could dent the gains.
NEW YORK, Dec. 9, 2020 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., today announced the successful spin-off of substantially all of the legacy assets and liabilities of Neurotrope, Inc. into the newly renamed company which is trading under the new symbol: SNPX.
NEW YORK, May 26, 2020 /PRNewswire/ — Neurotrope, Inc. (Nasdaq: NTRP) today announced that it will host an investor conference call and webcast to give an update on Bryostatin and the recently proposed merger between Neurotrope and Metuchen Pharmaceuticals, L.L.C. to form Petros Pharmaceuticals, Inc. The investor call is scheduled for Thursday, May 28, 2020 at 11:00 AM ET.
Neurotrope’s (NTRP +3.0%) Board of Directors approved the conditional distribution in connection with the previously announced spin-off of its wholly-owned subsidiary, Neurotrope Bioscience, Inc.
BryoLogyx Inc. has entered into two agreements with Neurotrope, Inc. to acquire Neurotrope’s preclinical data and drug product bryostatin-1 for an immuno-oncology application, and to supply Neurotrope with synthetic bryostatin-1 for clinical trials and commercialization for the treatment of Alzheimer’s disease and other neurodegenerative diseases. Neurotrope has been developing bryostatin-1 under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Financial terms were not disclosed.
NEW YORK, May 26, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) today announced that it will host an investor conference call and webcast to give an update on Bryostatin and the recently proposed merger between Neurotrope and Metuchen Pharmaceuticals, L.L.C. to form Petros Pharmaceuticals, Inc. The investor call is scheduled for Thursday, May 28, 2020 at 11:00 AM ET.
NEW YORK, May 26, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) today announced that it will host an investor conference call and webcast to give an update on Bryostatin and the recently proposed merger between Neurotrope and Metuchen Pharmaceuticals, L.L.C. to form Petros Pharmaceuticals, Inc. The investor call is scheduled for Thursday, May 28, 2020 at 11:00 AM ET.